Search
Menu
Rocky Mountain Instruments - Infrared Optics LB

Endocyte Inc.

Facebook X LinkedIn Email
Endocyte Inc. of West Lafayette, Ind., has initiated a randomized Phase II clinical study of its EC145 drug in women with platinum-resistant ovarian cancer. In addition to the drug, patients will be treated with the company’s EC20 molecular imaging agent, which enables clinicians to identify tumors that overexpress folate receptors.Read full article

Related content from Photonics Media



    Articles


    Products


    Photonics Handbook Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories


    Companies
    Published: April 2009
    BiophotonicsEndocyte Inc.molecular imagingNews & Features

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.